Uwe Lendeckel

Dr. Uwe Lendeckel

University Medicine Greifswald, Institute of Medical Biochemistry and Molecular Biology, University of Greifswald, Ferdinand-Sauerbruch-Strasse, D-17475 Greifswald, Germany
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2022 in ChemTexts
Verified
Journal Article
Open access
PDF file
Uwe LendeckelUwe Lendeckel
Uwe Lendeckel
SVSimone Venz
Simone Venz
CWCarmen Wolke
Carmen Wolke
Macrophages are cells of the innate immune system and represent an important component of the first-line defense against pathogens and tumor cells. Here, their diverse functions in inflammation and tumor defense are described, and the mechanisms, tools, and activation pathways and states applied are presented. The main focus is on the role and origin of reactive oxygen species (ROS), the important signal pathways TLR/NF-κB, and the M1/​​M2 polarization of macrophages.Graphical abstract

30 September 2021 in Cells
Verified
Journal Article
Open access
PDF file
Andreas GoetteAndreas Goette
Andreas Goette
Uwe LendeckelUwe Lendeckel
Uwe Lendeckel
Around the world there are 33.5 million patients suffering from atrial fibrillation (AF) with an annual increase of 5 million cases. Most AF patients have an established form of an atrial cardiomyopathy. The concept of atrial cardiomyopathy was introduced in 2016. Thus, therapy of underlying diseases and atrial tissue changes appear as a cornerstone of AF therapy. Furthermore, therapy or prevention of atrial endocardial changes has the potential to reduce atrial thrombogenesis and thereby cerebral stroke. The present manuscript will summarize the underlying pathophysiology and remodeling processes observed in the development of an atrial cardiomyopathy, thrombogenesis, and atrial fibrillation. In particular, the impact of oxidative stress, inflammation, diabetes, and obesity will be addressed.

1 May 2015 in International Journal of Cardiology
Verified
Journal Article
Closed access
RCR.K. Chilukoti
R.K. Chilukoti
AGA. Giese
A. Giese
WMW. Malenke
W. Malenke
GHG. Homuth
G. Homuth
ABA. Bukowska
A. Bukowska
CWC. Wolke
C. Wolke

1 January 2014 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
HGHans J Grabe
Hans J Grabe
HAHeinrich Assel
Heinrich Assel
TBThomas Bahls
Thomas Bahls
MDMarcus Dörr
Marcus Dörr
KEKarlhans Endlich
Karlhans Endlich
HKHeyo K Kroemer
Heyo K Kroemer
Individualized Medicine aims at providing optimal treatment for an individual patient at a given time based on his specific genetic and molecular characteristics. This requires excellent clinical stratification of patients as well as the availability of genomic data and biomarkers as prerequisites for the development of novel diagnostic tools and therapeutic strategies. The University Medicine Greifswald, Germany, has launched the “Greifswald Approach to Individualized Medicine” (GANI_MED) project to address major challenges of Individualized Medicine. Herein, we describe the implementation of the scientific and clinical infrastructure that allows future translation of findings relevant to Individualized Medicine into clinical practice. Clinical patient cohorts (N > 5,000) with an emphasis on metabolic and cardiovascular diseases are being established following a standardized protocol for the assessment of medical history, laboratory biomarkers, and the collection of various biosamples for bio-banking purposes. A multi-omics based biomarker assessment including genome-wide genotyping, transcriptome, metabolome, and proteome analyses complements the multi-level approach of GANI_MED. Comparisons with the general background population as characterized by our Study of Health in Pomerania (SHIP) are performed. A central data management structure has been implemented to capture and integrate all relevant clinical data for research purposes. Ethical research projects on informed consent procedures, reporting of incidental findings, and economic evaluations were launched in parallel.

1 August 2015 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
CWCarmen Wolke
Carmen Wolke
ABAlicja Bukowska
Alicja Bukowska
AGAndreas Goette
Andreas Goette
Uwe LendeckelUwe Lendeckel
Uwe Lendeckel

14 August 2013 in International Journal of Molecular Medicine
Verified
Journal Article
Open access
PDF file
CHCarmen Härdtner
Carmen Härdtner
CMCaroline Mörke
Caroline Mörke
RWReinhard Walther
Reinhard Walther
CWCarmen Wolke
Carmen Wolke
Uwe LendeckelUwe Lendeckel
Uwe Lendeckel
The activation of the classical angiotensin (Ang)-converting enzyme (ACE)/Ang II/Ang II type 1 receptor (AT1R) axis of the renin-angiotensin system (RAS) has been associated with islet dysfunction and insulin resistance. Hyperglycaemia, hypertension and obesity, major components of metabolic syndrome, are all associated with increased systemic and tissue levels of Ang II. Whereas it is well established that Ang II, by binding to AT1R, impairs glucose-stimulated insulin secretion and insulin signaling, the contribution of alternative RAS axes to β-cell function remains to be fully elucidated. In this study, using the BRIN-BD11 rat insulinoma cell line, we i) examined the basal expression levels of components of classical and alternative RAS axes and ii) investigated the effects of normal (5.5 mM) and elevated (11, 15, 25 mM) glucose concentrations on their expression and/or enzymatic activity by means of reverse transcription quantitative PCR (RT-qPCR), immunoblot analysis and enzymatic activity assays. The results correlated with the insulin production and release. Essential components of all RAS axes were found to be expressed in the BRIN-BD11 cells. Components of the alternative RAS axes, ACE2, neutral endopeptidase 24.11, Mas receptor (Mas), aminopeptidases A (APA) and N (APN) and insulin-regulated aminopeptidase (IRAP) showed an increased expression/activity in response to high glucose. These alterations were paralleled by the glucose-dependent increase in insulin production and release. By contrast, components of the classical RAS axis, ACE, AT1R and Ang II type 2 receptor (AT2R), remained largely unaffected under these conditions. Glucose induced the activation of the alternative ACE2/Ang-(1-7)/Mas and APN/Ang IV/IRAP RAS axes simultaneously with the stimulation of insulin production/release. Our data suggest the existence of a functional link between the local RAS axis and pancreatic β-cell function; however, further studies are required to confirm this hypothesis.